{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:29:07Z","timestamp":1777577347841,"version":"3.51.4"},"reference-count":68,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1129391"],"award-info":[{"award-number":["OPP1129391"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Risk Analysis"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Countries face different poliovirus risks, which imply different benefits associated with continued and future use of oral poliovirus vaccine (OPV) and\/or inactivated poliovirus vaccine (IPV). With the Global Polio Eradication Initiative (GPEI) continuing to extend its timeline for ending the transmission of all wild polioviruses and to introduce new poliovirus vaccines, the polio vaccine supply chain continues to expand in complexity. The increased complexity leads to significant uncertainty about supply and costs. Notably, the strategy of phased OPV cessation of all three serotypes to stop all future incidence of poliomyelitis depends on successfully stopping the transmission of all wild polioviruses. Countries also face challenges associated with responding to any outbreaks that occur after OPV cessation, because stopping transmission of such outbreaks requires reintroducing the use of the stopped OPV in most countries. National immunization program leaders will likely consider differences in their risks and willingness\u2010to\u2010pay for risk reduction as they evaluate their investments in current and future polio vaccination. Information about the costs and benefits of future poliovirus vaccines, and discussion of the complex situation that currently exists, should prove useful to national, regional, and global decisionmakers and support health economic modeling. Delays in achieving polio eradication combined with increasing costs of poliovirus vaccines continue to increase financial risks for the GPEI.<\/jats:p>","DOI":"10.1111\/risa.13557","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T16:28:24Z","timestamp":1594312104000},"page":"349-363","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Potential Future Use, Costs, and Value of Poliovirus Vaccines"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-9147","authenticated-orcid":false,"given":"Kimberly M.","family":"Thompson","sequence":"first","affiliation":[{"name":"Kid Risk, Inc.  Orlando FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika A.","family":"Kalkowska","sequence":"additional","affiliation":[{"name":"Kid Risk, Inc.  Orlando FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.039"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0672-z"},{"issue":"9","key":"e_1_2_9_4_1","first-page":"683","article-title":"Eradication versus control: The economics of global infectious disease policies","volume":"82","author":"Barrett S.","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_9_5_1","unstructured":"Bureau of Labor Statistics U.S. Department of Labor. (2020).Consumer price index. Retrieved fromhttps:\/\/www.bls.gov\/cpi\/data.htm"},{"key":"e_1_2_9_6_1","unstructured":"Centers for Disease Control and Prevention. (2008).Archived CDC Vaccine Price List as of September 23 2008. Retrieved fromhttps:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/2008\/2008-09-23.html#f4"},{"key":"e_1_2_9_7_1","unstructured":"Centers for Disease Control and Prevention. (2019).VFC CDC Vaccine Price List Archives. Retrieved fromhttps:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/archive.html"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2012.01864.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12031"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.026"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00827.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12022"},{"issue":"379","key":"e_1_2_9_13_1","article-title":"Modeling the prevalence of immunodeficiency\u2010associated long\u2010term vaccine\u2010derived poliovirus excretors and the potential benefits of antiviral drugs","volume":"15","author":"Duintjer Tebbens R. J.","year":"2015","journal-title":"BMC Infectious Diseases"},{"issue":"389","key":"e_1_2_9_14_1","article-title":"An economic analysis of poliovirus risk management policy options for 2013\u20132052","volume":"15","author":"Duintjer Tebbens R. J.","year":"2015","journal-title":"BMC Infectious Diseases"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00842.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7560.1000339"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2381468317697002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1322514"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1506333"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.089"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60531-5"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu674"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit834"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit844"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881900181X"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13471"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13447"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13555"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068284"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.10.2893-2899.1998"},{"key":"e_1_2_9_31_1","unstructured":"Leo L.(2019).Panacea Biotec eyes $1 billion hexavalent vaccine\u200amarket. Retrieved fromhttps:\/\/www.livemint.com\/companies\/news\/panacea-biotec-eyes-1-billion-hexavalent-vaccinemarket-11577638313938.html"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.276.12.967"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13011-0"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep22094"},{"issue":"1","key":"e_1_2_9_35_1","first-page":"1","article-title":"Is polio eradication in the Americas economically justified?","volume":"22","author":"Musgrove P.","year":"1988","journal-title":"Bulletin of the Pan American Health Organization"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100032"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq320"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000964"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu184"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.12.037"},{"issue":"4","key":"e_1_2_9_41_1","first-page":"35","article-title":"Policy decision options during the first 5 years following certification of polio eradication","volume":"5","author":"Sangrujee N.","year":"2003","journal-title":"Medscape General Medicine"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00831.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60532-7"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.195"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.864563"},{"issue":"376","key":"e_1_2_9_46_1","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype\u2010specific population immunity to poliovirus transmission","volume":"15","author":"Thompson K. M.","year":"2015","journal-title":"BMC Infectious Diseases"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.122192"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1635463"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13484"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12019"},{"key":"e_1_2_9_51_1","unstructured":"UNICEF. (2019).UNICEF Supply and Logistics \u2010 Vaccine price data (IPV last updated 25 October 2018 OPV last updated 25 July 2019). Retrieved fromhttps:\/\/www.unicef.org\/supply\/index_57476.html"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31279-6"},{"key":"e_1_2_9_53_1","unstructured":"World Bank. (2019).World Bank list of economies (June 2019). Retrieved fromhttp:\/\/databank.worldbank.org\/data\/download\/site-content\/CLASS.xls"},{"key":"e_1_2_9_54_1","unstructured":"World Health Assembly. (1988).Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Retrieved fromhttp:\/\/www.who.int\/csr\/ihr\/polioresolution4128en.pdf"},{"key":"e_1_2_9_55_1","unstructured":"World Health Assembly. (2008).Poliomyelitis: Mechanism for management of potential risks to eradication (resolution 61.1). Retrieved fromhttp:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA61-REC1\/A61_Rec1-part2-en.pdf"},{"key":"e_1_2_9_56_1","unstructured":"World Health Organization. (2008).WHO guide for standardization of economic evaluations of immunization programmes (WHO\/IVB\/0814). Retrieved from Geneva: Retrieved fromhttp:\/\/whqlibdoc.who.int\/hq\/2008\/WHO_IVB_08.14_eng.pdf"},{"issue":"1","key":"e_1_2_9_57_1","first-page":"1","article-title":"Meeting of the strategic advisory group of experts on immunization, November 2013 \u2010 Conclusions and recommendations","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_9_58_1","unstructured":"World Health Organization. (2014b September).WHO policy statement: Multi\u2010dose vial policy (MDVP) \u2013 Revision 2014. Retrieved fromhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/135972\/1\/WHO_IVB_14.07_eng.pdf"},{"key":"e_1_2_9_59_1","unstructured":"World Health Organization. (2016a).The global switch: As it happens. Retrieved fromhttp:\/\/polioeradication.org\/news-post\/the-global-switch-as-it-happens\/"},{"key":"e_1_2_9_60_1","unstructured":"World Health Organization. (2016b).SAGE confirms global polio vaccine switch date as April 2016. Retrieved frompolioeradication.org\/news-post\/sage-confirms-global-polio-vaccine-switch-date-as-april-2016\/"},{"issue":"22","key":"e_1_2_9_61_1","first-page":"301","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2017 \u2010 Conclusions and recommendations","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_9_62_1","unstructured":"World Health Organization. (2019a).Two out of three wild poliovirus strains eradicated. Retrieved fromhttps:\/\/www.who.int\/news-room\/feature-stories\/detail\/two-out-of-three-wild-poliovirus-strains-eradicated"},{"key":"e_1_2_9_63_1","unstructured":"World Health Organization. (2019b).WHO guide for standardization of economic evaluations of immunization programmes Edition II October 2019 (WHO\/IVB\/19.10). Retrieved from Geneva: Retrieved fromhttps:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329389\/WHO-IVB-19.10-eng.pdf"},{"key":"e_1_2_9_64_1","unstructured":"World Health Organization. (2020).Polio this week as of 19 February 2020. Retrieved fromhttp:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/"},{"key":"e_1_2_9_65_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2013).Polio eradication and endgame Strategic Plan (2013\u20102018)(Report No: WHO\/POLIO\/13.02). Geneva. Retrieved fromhttp:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf"},{"key":"e_1_2_9_66_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2019).Polio eradication and endgame strategic plan (2019\u20102023)(Report No: WHO\/POLIO\/19.04). Geneva. Retrieved fromhttp:\/\/polioeradication.org\/wp-content\/uploads\/2019\/05\/polio-endgame-strategy-2019-2023.pdf"},{"key":"e_1_2_9_67_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2020).Strategy for the response to type 2 circulating vaccine\u2010derived poliovirus 2020\u20132021: Addendum to the Polio eradication and endgame strategic plan (2019\u20102023). (Report No: WHO\/POLIO\/20.02). Geneva. Retrieved fromhttp:\/\/polioeradication.org\/"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0698"},{"issue":"4","key":"e_1_2_9_69_1","first-page":"561","article-title":"Projection of costs of polio eradication compared to permanent control","volume":"221","author":"Zimmermann M.","year":"2020","journal-title":"Journal of Infectious Diseases"}],"container-title":["Risk Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Frisa.13557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/risa.13557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/risa.13557","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/risa.13557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:54:20Z","timestamp":1693684460000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/risa.13557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/risa.13557"],"URL":"https:\/\/doi.org\/10.1111\/risa.13557","archive":["Portico"],"relation":{},"ISSN":["0272-4332","1539-6924"],"issn-type":[{"value":"0272-4332","type":"print"},{"value":"1539-6924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"2020-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}